542 related articles for article (PubMed ID: 18068807)
1. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders.
Heal DJ; Smith SL; Fisas A; Codony X; Buschmann H
Pharmacol Ther; 2008 Feb; 117(2):207-31. PubMed ID: 18068807
[TBL] [Abstract][Full Text] [Related]
2. Serotonin receptor ligands and the treatment of obesity.
Vickers SP; Dourish CT
Curr Opin Investig Drugs; 2004 Apr; 5(4):377-88. PubMed ID: 15134278
[TBL] [Abstract][Full Text] [Related]
3. Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands.
Holenz J; Mercè R; Díaz JL; Guitart X; Codony X; Dordal A; Romero G; Torrens A; Mas J; Andaluz B; Hernández S; Monroy X; Sánchez E; Hernández E; Pérez R; Cubí R; Sanfeliu O; Buschmann H
J Med Chem; 2005 Mar; 48(6):1781-95. PubMed ID: 15771424
[TBL] [Abstract][Full Text] [Related]
4. Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents.
Holenz J; Pauwels PJ; Díaz JL; Mercè R; Codony X; Buschmann H
Drug Discov Today; 2006 Apr; 11(7-8):283-99. PubMed ID: 16580970
[TBL] [Abstract][Full Text] [Related]
5. In the search for selective ligands of 5-HT5, 5-HT6 and 5-HT7 serotonin receptors.
Wesołowska A
Pol J Pharmacol; 2002; 54(4):327-41. PubMed ID: 12523486
[TBL] [Abstract][Full Text] [Related]
6. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling.
Hirst WD; Abrahamsen B; Blaney FE; Calver AR; Aloj L; Price GW; Medhurst AD
Mol Pharmacol; 2003 Dec; 64(6):1295-308. PubMed ID: 14645659
[TBL] [Abstract][Full Text] [Related]
7. 5-HT6 receptor antagonists: prospects for the treatment of cognitive disorders including dementia.
Johnson CN; Ahmed M; Miller ND
Curr Opin Drug Discov Devel; 2008 Sep; 11(5):642-54. PubMed ID: 18729016
[TBL] [Abstract][Full Text] [Related]
8. Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases.
Wacker DA; Miller KJ
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):438-45. PubMed ID: 18600561
[TBL] [Abstract][Full Text] [Related]
9. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
[TBL] [Abstract][Full Text] [Related]
10. Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.
Ahmad S; Ngu K; Miller KJ; Wu G; Hung CP; Malmstrom S; Zhang G; O'Tanyi E; Keim WJ; Cullen MJ; Rohrbach KW; Thomas M; Ung T; Qu Q; Gan J; Narayanan R; Pelleymounter MA; Robl JA
Bioorg Med Chem Lett; 2010 Feb; 20(3):1128-33. PubMed ID: 20022752
[TBL] [Abstract][Full Text] [Related]
11. Novel 2-aminotetralin and 3-aminochroman derivatives as selective serotonin 5-HT7 receptor agonists and antagonists.
Holmberg P; Sohn D; Leideborg R; Caldirola P; Zlatoidsky P; Hanson S; Mohell N; Rosqvist S; Nordvall G; Johansson AM; Johansson R
J Med Chem; 2004 Jul; 47(16):3927-30. PubMed ID: 15267230
[TBL] [Abstract][Full Text] [Related]
12. The 5-HT6 receptor as a target for developing novel antiobesity drugs.
Heal D; Gosden J; Smith S
Int Rev Neurobiol; 2011; 96():73-109. PubMed ID: 21329785
[No Abstract] [Full Text] [Related]
13. Addressing the unmet medical need for safe and effective weight loss therapies.
Arbeeny CM
Obes Res; 2004 Aug; 12(8):1191-6. PubMed ID: 15340099
[TBL] [Abstract][Full Text] [Related]
14. Actions of novel agonists, antagonists and antipsychotic agents at recombinant rat 5-HT6 receptors: a comparative study of coupling to G alpha s.
Dupuis DS; Mannoury la Cour C; Chaput C; Verrièle L; Lavielle G; Millan MJ
Eur J Pharmacol; 2008 Jul; 588(2-3):170-7. PubMed ID: 18511034
[TBL] [Abstract][Full Text] [Related]
15. 1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.
Vachal P; Fletcher JM; Fong TM; Huang CC; Lao J; Xiao JC; Shen CP; Strack AM; Shearman L; Stribling S; Chen RZ; Frassetto A; Tong X; Wang J; Ball RG; Tsou NN; Hickey GJ; Thompson DF; Faidley TD; Nicolich S; Achanfuo-Yeboah J; Hora DF; Hale JJ; Hagmann WK
J Med Chem; 2009 Apr; 52(8):2550-8. PubMed ID: 19320488
[TBL] [Abstract][Full Text] [Related]
16. Novel 1-(azacyclyl)-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines as 5-HT6 agonists and antagonists.
Elokdah H; Li D; McFarlane G; Bernotas RC; Robichaud AJ; Magolda RL; Zhang GM; Smith D; Schechter LE
Bioorg Med Chem; 2007 Sep; 15(18):6208-26. PubMed ID: 17624788
[TBL] [Abstract][Full Text] [Related]
17. Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity.
Alig L; Alsenz J; Andjelkovic M; Bendels S; Bénardeau A; Bleicher K; Bourson A; David-Pierson P; Guba W; Hildbrand S; Kube D; Lübbers T; Mayweg AV; Narquizian R; Neidhart W; Nettekoven M; Plancher JM; Rocha C; Rogers-Evans M; Röver S; Schneider G; Taylor S; Waldmeier P
J Med Chem; 2008 Apr; 51(7):2115-27. PubMed ID: 18335976
[TBL] [Abstract][Full Text] [Related]
18. Potential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors.
Jensen MD
Obesity (Silver Spring); 2006 Jun; 14 Suppl 3():143S-149S. PubMed ID: 16931496
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.
Liu KK; Cornelius P; Patterson TA; Zeng Y; Santucci S; Tomlinson E; Gibbons C; Maurer TS; Marala R; Brown J; Kong JX; Lee E; Werner W; Wenzel Z; Vage C
Bioorg Med Chem Lett; 2010 Jan; 20(1):266-71. PubMed ID: 19914063
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Ro 04-6790 and Ro 63-0563: potent and selective antagonists at human and rat 5-HT6 receptors.
Sleight AJ; Boess FG; Bös M; Levet-Trafit B; Riemer C; Bourson A
Br J Pharmacol; 1998 Jun; 124(3):556-62. PubMed ID: 9647481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
